Do Tregitopes have the potential to impact the current treatment landscape of autoimmune diseases?

Anne S. De Groot

*University of Rhode Island, annied@uri.edu*

---

The University of Rhode Island Faculty have made this article openly available. Please let us know how Open Access to this research benefits you.

This is a pre-publication author manuscript of the final, published article.

**Citation/Publisher Attribution**

De Groot, A. S. (2013). Do Tregitopes have the potential to impact the current treatment landscape of autoimmune diseases? *Expert Review of Clinical Immunology, 9*(12), 1155-1157.

Available at: [http://dx.doi.org/10.1586/1744666X.2013.858602](http://dx.doi.org/10.1586/1744666X.2013.858602)
Do Tregitopes have the potential to impact the current treatment landscape of autoimmune diseases?

Anne S. De Groot¹,²

¹EpiVax, Inc., 146 Clifford Street, Providence, RI 02903, USA and ²Institute for Immunology and Informatics, 80 Washington Street, Providence, RI 02903, USA

Abstract

Current treatment of autoimmune disease usually involves the use of cytotoxic drugs or biologic agents that interfere with the activity of B cells, T cells or key cytokines, such as TNF, IL-1 and IL-6. On occasion, polyclonal immunoglobulin G (IgG), intravenous (IVIg) is used. The discovery of IgG- (and hence IVIg-) derived T regulatory (Treg) epitopes that trigger the expansion of Tregs in vitro and in vivo provides a novel explanation for the effect of IVIg. These IgG-derived Treg epitopes (also known as Tregitopes) appear to be effective on their own (in vivo, in autoimmune disease models) and when co-administered with a specific autoimmune disease antigen, contribute to antigen-specific tolerance induction. A description of Tregitopes and a brief discussion of their potential applications in autoimmune disease are provided here. Tregitope-based immunotherapy has the potential to modify the current autoimmune pharmacopeia.

Tregitopes are regulatory T-cell epitope sequences contained in IgG that were discovered by the team of De Groot and Martin in the course of searching for T effector (Teff) epitopes in monoclonal antibody (mAb) therapeutics [1,2]. These highly conserved (in IgG), promiscuous Treg epitopes have been shown to trigger the expansion of Tregs in vitro. A retrospective review of the T-cell epitope (and Tregitope) content of therapeutic mAbs, published in 2009 [3], revealed a close correlation between the presence of Tregitopes and the absence of HLA-binding Teff epitopes, with the lack of mAb immunogenicity in clinical use.

Taking this observation one step further, the presence of Treg epitopes in IgG might explain why immunoglobulins, which are produced by B cells that undergo somatic hypermutation in the periphery, do not generally elicit the expected immune response against the new ‘foreign’ hypervariable (complementarity determining regions, or CDR) sequences. Recognition of the importance of Tregitopes in mAb therapeutics led to the incorporation of Tregitope specific adjustments in certain immunogenicity predictions, improving the accuracy of the results [4,5].

Tregitopes may also explain, in part, the tolerance-inducing effect of intravenous immunoglobulin (IVIg) therapy [6]. This theory is supported by reports that IVIg-induced expansion of Tregs in vitro and in vivo, [7–9], and IVIg experts generally agree that Treg epitopes such as Tregitopes may be contributing to the tolerizing effects of IVIg [10,11]. Although it is only approved for use in a handful of diseases [12], IVIg is used off-label for hundreds of conditions [13–19].

Recently published in vivo studies of Tregitopes in mouse models of human autoimmune diseases have further validated the Tregitope discovery [20]. Additional publications demonstrate that co-administration of Tregitopes with target antigens in vivo and in vitro leads to the induction of antigen-specific tolerance [2,21] and suppression of both humoral [22] and cellular immune responses, including antigen-specific CD8+ T-cell response [6,23]. ‘Control’ peptides have been compared in vitro and in vivo [24] and have not been shown to have the same effect. In another recent publication, cross-conservation (at the T-cell receptor surface) with other highly conserved T-cell epitopes in autologous proteins is identified as a potential distinguishing feature of Treg epitopes (such as Tregitopes) but not from Teff epitopes [25].
Other groups have reported that specific IgG-derived peptides subsequently identified as Tregitopes [26–28] induce tolerance in animal and human autoimmune disease, providing independent confirmation of Tregitope studies. The proposed Tregitope mechanism of action is distinct from some IVIg mechanisms of action but similar to others (FIGURE 1). For example, Tregitopes are unlikely to be involved in the induction of tolerance by the formation of immune complexes, blockade of Fc receptors and thereby clearance of anti-self-antibodies; immuno-modulation via antiidiotypic interactions, inhibition of complement-mediated tissue damage and inhibition of superantigen-mediated T-cell activation; but may be involved in tolerance induction following interaction of sialylated Fc with DC-SIGN, and in direct modulation of cytokine expression (by Tregs); as well as induction of Tregs [13]. IVIg has also recently been shown to be associated with modulation of the regulatory T-cell axis, reduction of IL-17 and enhancement of the suppressive function of Tregs. Many of these effects can be explained by uptake of Tregitope by antigen-presenting cells, processing and presentation of Tregitopes to T cells, which respond by inducing Tregs to be activated and express FoxP3 and CD25. IgG processing and epitope presentation is likely to occur when the IgG recycling protein, FcRN, is overwhelmed (as it may be when high doses of IgG, as in IVIg, are given).

The discovery of Tregitopes naturally led to the concept of actively integrating Tregitopes into biologics. Tolerization of immune responses to protein therapeutics (by introduction of Tregitopes) could be considered to be an alternative to humanization of mAbs, and it might also be applied to non-mAb biologic products [20]. Tolerization across the breadth of HLA alleles expressed in the general human population would involve inclusion of the complete repertoire of Tregitopes present in each IgG that is developed for clinical applications. Studies that support the effectiveness of this approach have been carried out by De Groot and Cousens et al. [6,20,21] and are currently underway in the laboratories of a number of other research groups [22,23]. The origin of Tregitope-specific T cells is as yet undetermined. They may be natural Tregs, induced Tregs or both. Regardless of the origin or mechanism of action of Tregitopes, the potential for these peptides to alter the course of autoimmune diseases as a replacement for cytotoxic therapy, or as an alternative to biological disease modifiers, is certainly worth consideration. Albumin has been proposed as a carrier for Tregitopes, since albumin itself may contain Tregitopes, and it has been used with a wide range of therapeutic proteins as a stable and non-immunogenic excipient.

Tregitopes may also be useful for their IVIg-like effects in conditions such as allergy, where Treg induction is considered to be important but IVIg was considered to be too dangerous (and expensive) to use as therapy. Tregitopes could be combined with the target of autoimmunity, where the target is known, such as glutamic acid decarboxylase (GAD 65) protein in diabetes. For example, early studies in autoimmune disease models clearly demonstrate that Tregitopes have promise as a standalone treatment for autoimmune disease [6,20]. Where the antigen is unknown, Tregitope immunotherapy might be given during a flare, when autoimmune antigens are being presented to the immune system by activated antigen-presenting cells. Whether used on their own, or co administered with a specific autoimmune disease antigen, Tregitope-based immunotherapy has the potential to augment future therapeutic options for autoimmune disease.

Acknowledgements
The assistance of R Martin, K Confreda and LP Cousens with the preparation of the manuscript and figures is sincerely appreciated. Artwork was designed and contributed by GS De Groot. The author also thanks DW Scott for a critical reading of the manuscript prior to submission.
Financial & competing interests disclosure
The author is founder and majority owner of EpiVax, Inc., a biotechnology company that provides immunogenicity screening services and access to the Tregitope technology on a fee-for-service basis. Due to this relationship with EpiVax, the author acknowledges that there is a potential conflict of interest inherent in the publication of this manuscript, and asserts that she made an effort to reduce or eliminate that conflict where possible. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

References


23 Hui DJ, Basner-Tschakarjan E, Chen Y et al. Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes. Mol Ther. 21(9), 1727–1737 (2013).


